EGCG with inhibitory effect on streptococcus pneumoniae pathogenicity and application

Abstract

The invention discloses an EGCG with an inhibitory effect on streptococcus pneumoniae pathogenicity and an application of EGCG with the inhibitory effect on the streptococcus pneumoniae pathogenicity for confirming that EGCG has no bacteriostatic activity for streptococcus pneumoniae, but can inhibit peptidase activity of SrtA to lower the pathogenicity of the streptococcus pneumoniae; the invention further provides a new pharmaceutical use of EGCG. Drug sensitivity tests, SrtA peptidase activity inhibition tests, Hep2 adherence inhibition tests and treatment tests of streptococcus pneumoniae infected mice confirm that EGCG plays a role of lowering the streptococcus pneumoniae pathogenicity.

Description

technical field [0001] The invention relates to the inhibition of the pathogenicity of Streptococcus pneumoniae by epigallocatechin gallate and its application, relates to the application of epigallocatechin gallate in reducing the pathogenicity of Streptococcus pneumoniae, and belongs to the field of medicine. Background technique [0002] Epigallocatechin gallate (EGCG) is a component with the highest content in green tea polyphenols, which has various pharmacological activities, such as anti-inflammatory, anti-oxidation, anti-fungal, anti-viral and anti-tumor, etc. Medicine already has an important place. But at present, there is no report of EGCG used in Streptococcus pneumoniae infection at home and abroad. [0003] Streptococcus pneumoniae is a Gram-positive opportunistic bacterium that colonizes the nasopharynx of humans asymptomatically. When the body's immunity is weakened, Streptococcus pneumoniae can cause local infections such as acute sinusitis and otitis medi...

AI Technical Summary

Problems solved by technology

But at present, there are no reports of EGCG being used f

Images